Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

Table 3 Immunologic response to cART according to mode of cART initiation (cART initiation during CHI versus cART resumption) from linear mixed-effects models with 3 slopes

Parameter	Univariate estimate	SE	Pvalue	Adjusted estimate^b	SE	Pvalue
Intercept √CD4 cART (reference)	19.085	0.235	<0.0001
cART resumption vs Initiation during CHI^a	1.012	0.482	0.04	−0.067	0.347	0.8
Slope 1 (0-3mo) √CD4/month (ref)	0.995	0.058	<0.0001
cART resumption vs initiation during CHI^a	0.118	0.126	0.4	0.063	0.129	0.5
Slope 2 (3–12 mo) √CD4/month (ref)	0.222	0.018	<0.0001
cART resumption vs initiation during CHI^a	−0.071	0.036	0.06	−0.056	0.038	0.1
Slope 3 > 12 mo √CD4/month (ref.)	0.070	0.007	<0.0001
cART resumption vs initiation during CHI^a	−0.029	0.011	0.01	−0.024	0.012	0.04

^aDifference between cART resumption and cART initiation during CHI (reference).
^bAdjusted in multivariate analysis, for age (≥40 versus <40 years), calendar period, HIV-RNA level (≥5 log versus <5), active smoking at cART initiation/resumption, HIV transmission group (homosexual men, heterosexual men, women), geographic origin, time since HIV infection, HIV subtype (B versus non B), baseline genotypic resistance, and CD4 cell count at PHI diagnosis.

ISSN: 1471-2334